Floatz logo

Tagraxofusp

CD4+/CD56+ Hematodermic Neoplasm

French Innovative Leukemia Organisationprotein_peptidePhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the CD4+/CD56+ Hematodermic Neoplasm cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2BB
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
Methotrexate
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2BB
Dexasone
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2B
Cytarabine
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2B

View all 47 →

Same molecule, other indications

Tagraxofusp is also rated in:

acute myeloid leukemiaActive
B
Indicative · Phase 2
56 / 100
View asset →
hematopoietic and lymphoid system neoplasmActive
CC
Indicative · Phase 1/2
47 / 100
View asset →
acute undifferentiated leukemiaActive
CC
Indicative · Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →